MRTX News and Press, Mirati Therapeutics Inc. From 09/20/21

Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors PR Newswire SAN DIEGO , Sept. 20, 2021 /PRNews...

Mirati Therapeutics Appoints David Meek as Chief Executive Officer Charles M. Baum, M.D., Ph.D to Continue in New Role of President, Founder and Head of Research and Development PR Newswire SAN DIEGO , Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics,...

Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer Company to host Virtual Investor Event on September 20, 2021 at 8:30 a.m. ET / 5:30 a.m. PT PR Newswire ...

Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer PR Newswire SAN DIEGO , Sept. 19, 2021 /PRNewswire/ -- Mirati Therapeutics, ...

Mirati Therapeutics to Host Virtual Investor Event on Monday, September 20, 2021 PR Newswire SAN DIEGO , Sept. 15, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will...

Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers - Late-breaking colorectal cancer data from a cohort of the Phase 1/2 KRYSTAL-1 study to be featured in ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in biotech stocks is not everyone’s cup of tea. A lot of it is because of the volatility that comes with investing in them. The reason for the volatile swings in biotech stocks is that they tend to trade ...

Mirati Therapeutics (NASDAQ:MRTX): Q2 GAAP EPS of -$3.23 misses by $0.78. Cash, cash equivalents, and short-term investments of $1.2B Press Release For further details see: Mirati Therapeutics EPS misses by $0.78

For a while at least. The last time completed a set of 37 priors over the most recent 5 years which produced 33 (89%) winners. Including their 4 losers, that netted profits at an annual rate of +375% during the more than 3 ½ years of capital (and time) investment required. St...

Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , Aug. 5, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial ...